Thu Sep 18 02:12:56 UTC 2025: Here’s a summary of the text, followed by a news article version written from the perspective of “The Hindu,” an Indian newspaper:
**Summary:**
U.S. President Donald Trump has identified 23 countries, including India, China, Afghanistan, and Pakistan, as major drug transit or illicit drug-producing nations. He submitted this “Presidential Determination” to Congress, stating these countries pose a threat to U.S. safety and citizens by manufacturing and trafficking illicit drugs and precursor chemicals. While inclusion on the list doesn’t automatically reflect a government’s counter-drug efforts, it highlights the geographical, commercial, and economic factors that facilitate drug production and transit. Afghanistan, Bolivia, Burma, Colombia, and Venezuela were specifically cited for failing to make demonstrable efforts in counter-narcotics. China was singled out as the world’s largest source of precursor chemicals for fentanyl and other synthetic narcotics. Afghanistan, despite the Taliban’s drug ban, continues to fuel drug flows to international markets, supporting criminal groups and terrorists. Trump emphasized the fentanyl crisis in the U.S., calling it a national emergency and the leading cause of death for young adults.
**News Article:**
**From *The Hindu* (September 18, 2025):**
**India Among 23 Nations Named by U.S. as Major Drug Transit or Production Hubs**
*New York/Washington:* The United States, under President Donald Trump, has designated India, along with China, Afghanistan, and Pakistan, as a major drug transit or illicit drug-producing nation. The move, outlined in a “Presidential Determination” submitted to the U.S. Congress on Monday, raises concerns about the potential impact on Indo-U.S. relations and India’s image on the global stage.
The U.S. statement alleges that these nations, by manufacturing and trafficking illicit drugs and precursor chemicals, are threatening the safety and security of the United States and its citizens. While the U.S. State Department clarified that inclusion on the list does not necessarily reflect a country’s counter-drug efforts, the designation is based on a combination of geographical, commercial, and economic factors that enable the drug trade.
India’s inclusion on the list is likely to draw scrutiny of its efforts to combat drug trafficking and production. While the Indian government has implemented various measures to control the flow of narcotics, the U.S. designation suggests Washington believes more can be done.
China was particularly singled out for its role as the world’s leading source of precursor chemicals used in the production of fentanyl and other synthetic narcotics. Afghanistan, despite the Taliban’s announced ban on illegal drugs, was also criticized for continuing to be a major source of illicit drugs, with revenues from the trade allegedly supporting criminal groups and terrorists.
The move comes as the U.S. grapples with a severe opioid crisis, with fentanyl-related deaths reaching alarming levels. President Trump has declared the crisis a national emergency, emphasizing the urgency of addressing the sources and transit routes of illicit drugs entering the United States.
The Indian government is expected to respond to the U.S. designation and outline its ongoing efforts to combat drug trafficking. The designation could lead to increased pressure from the U.S. for greater cooperation in counter-narcotics efforts, potentially impacting trade and security relationships.
First Piper 